These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 19749205)
21. Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca Pinto-Martinez AK; Rodriguez-Durán J; Serrano-Martin X; Hernandez-Rodriguez V; Benaim G Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061745 [No Abstract] [Full Text] [Related]
22. Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole. Andrade-Neto VV; Pereira TM; Canto-Cavalheiro Md; Torres-Santos EC Parasit Vectors; 2016 Mar; 9():183. PubMed ID: 27036654 [TBL] [Abstract][Full Text] [Related]
23. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death. Mishra J; Singh S Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687 [TBL] [Abstract][Full Text] [Related]
24. Cellular transport and lipid interactions of miltefosine. Barratt G; Saint-Pierre-Chazalet M; Loiseau PM Curr Drug Metab; 2009 Mar; 10(3):247-55. PubMed ID: 19442087 [TBL] [Abstract][Full Text] [Related]
25. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization. Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880 [TBL] [Abstract][Full Text] [Related]
26. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Papagiannaros A; Bories C; Demetzos C; Loiseau PM Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367 [TBL] [Abstract][Full Text] [Related]
27. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome. Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089 [TBL] [Abstract][Full Text] [Related]
28. Novel Agents against Miltefosine-Unresponsive Leishmania donovani. Das M; Saha G; Saikia AK; Dubey VK Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497 [TBL] [Abstract][Full Text] [Related]
29. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model. Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955 [TBL] [Abstract][Full Text] [Related]
30. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060 [TBL] [Abstract][Full Text] [Related]
31. Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species. Das M; Saudagar P; Sundar S; Dubey VK FEBS J; 2013 Oct; 280(19):4807-15. PubMed ID: 23890327 [TBL] [Abstract][Full Text] [Related]
32. Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs. Rastrojo A; García-Hernández R; Vargas P; Camacho E; Corvo L; Imamura H; Dujardin JC; Castanys S; Aguado B; Gamarro F; Requena JM Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):246-264. PubMed ID: 29689531 [TBL] [Abstract][Full Text] [Related]
33. Perifosine Mechanisms of Action in Leishmania Species. López-Arencibia A; Martín-Navarro C; Sifaoui I; Reyes-Batlle M; Wagner C; Lorenzo-Morales J; Maciver SK; Piñero JE Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096161 [TBL] [Abstract][Full Text] [Related]
34. Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Pourshafie M; Morand S; Virion A; Rakotomanga M; Dupuy C; Loiseau PM Antimicrob Agents Chemother; 2004 Jul; 48(7):2409-14. PubMed ID: 15215088 [TBL] [Abstract][Full Text] [Related]
35. Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1. Pandharkar T; Zhu X; Mathur R; Jiang J; Schmittgen TD; Shaha C; Werbovetz KA Antimicrob Agents Chemother; 2014 Aug; 58(8):4682-9. PubMed ID: 24890590 [TBL] [Abstract][Full Text] [Related]
36. The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil. Morais-Teixeira Ed; Damasceno QS; Galuppo MK; Romanha AJ; Rabello A Mem Inst Oswaldo Cruz; 2011 Jun; 106(4):475-8. PubMed ID: 21739037 [TBL] [Abstract][Full Text] [Related]
37. Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. Ganguly S; Bandyopadhyay S; Sarkar A; Chatterjee M J Microbiol Methods; 2006 Jul; 66(1):79-86. PubMed ID: 16316700 [TBL] [Abstract][Full Text] [Related]
38. Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani. Veronica J; Chandrasekaran S; Dayakar A; Devender M; Prajapati VK; Sundar S; Maurya R FEBS J; 2019 Sep; 286(17):3488-3503. PubMed ID: 31087522 [TBL] [Abstract][Full Text] [Related]
39. Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection. Hendrickx S; Van Bockstal L; Bulté D; Mondelaers A; Aslan H; Rivas L; Maes L; Caljon G Parasit Vectors; 2020 Feb; 13(1):96. PubMed ID: 32087758 [TBL] [Abstract][Full Text] [Related]
40. In vitro 4-Aryloxy-7-chloroquinoline derivatives are effective in mono- and combined therapy against Leishmania donovani and induce mitocondrial membrane potential disruption. Valdivieso E; Mejías F; Torrealba C; Benaim G; Kouznetsov VV; Sojo F; Rojas-Ruiz FA; Arvelo F; Dagger F Acta Trop; 2018 Jul; 183():36-42. PubMed ID: 29604246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]